Assessment of treatment efficacy on venous symptoms: The example of Daflon 500 mg

Phlebolymphology

Volumn 15, Issue 4, 2008, Pages 137-142

  Pitsch, Françoise ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Assessment; Symptoms; Tools; Varicose veins

Indexed keywords

ANALGESIC AGENT; DAFLON; GENERIC DRUG; PLACEBO;

ARTICLE; BURNING SENSATION; CHRONIC VEIN INSUFFICIENCY; COMPRESSION THERAPY; DISEASE CLASSIFICATION; DRUG EFFICACY; EDEMA; FATIGUE; HUMAN; LEG PAIN; MUSCLE CRAMP; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; SCLEROTHERAPY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SHORT FORM 36; SWELLING; SYMPTOMATOLOGY; THERAPY EFFECT; VEIN SURGERY; VISUAL ANALOG SCALE;

EID: 56849094629     PISSN: 12860107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. The VENTERM Transatlantic Interdisciplinary Faculty. Chronic venous disorders terminology refinement. The VENTERM Transatlantic Interdisciplinary consensus document. J Vasc Surg. In press.
2. Carpentier P. Prevalence, risk factors and clinical significance of venous symptoms. Medicographia. 2006;28:168-170.
3. Langer RD, Ho E, Deneberg JO, et al. Relationships between symptoms and venous disease. Arch Int Med. 2005;165:1420-1424.
4. Scuderi A, Raskin B, Al Assal F, et al. The incidence of venous disease in Brazil based on the CEAP classification. An epidemiological study. Int Angiol. 2002:21:316-321.
5. Carpentier PH., Cornu-Thénard A, Uhl JF, Partsch HJF, Antignani PL. Appraisal of the information content of the C classes of CEAP clinical classification of chronic venous disorders. A multicenter series of 872 patients. J Vasc Surg. 2003;37:827-833.
6. Jawien A, Grzela T, Ochwat A. Prevalence of chronic venous insufficiency in men and women in Poland: multicentre cross-sectional study in 40095 patients. Phlebology. 2003;18:110-122.
7. Blanchemaison P. Evaluation pratique du risque veineux: le Phléboscore®. Act Vasc Int. 2000:81:12-16.
8. Lamping DL, Schroter S, Kurz X, Kahn SR, Abenhaim L. Evaluation of outcomes in chronic venous disorders of the leg: Development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. J Vasc Surg. 2003:37:410-419.
9. Carpentier PH, Poulain C, Fabry R, et al. Ascribing leg symptoms to chronic venous disorders: the construction of a diagnostic score. J Vasc Surg. 2007:46:991-996.
10. Vasquez MA. Venous Clinical Severity Score and Quality-of-Life Assessment Tools: Application to Vein Practice. J Vasc Surg. In press.
11. Eklöf B, Rutherford RB, Bergan JJ, et al; American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004:40:1248-1252.
12. Rutherford RB, Padberg FT Jr, Comerota AJ, Kistner RL, Meissner MH, Moneta GL; American Venous Forum's Ad Hoc Committee on Venous Outcomes Assessment. Venous severity scoring: An adjunct to venous outcome assessment. J Vasc Surg. 2000;31:1307-1312.
13. Perrin M, Dedieu F, Jessent V, Blanc MP. Evaluation of the new severity scoring system in chronic venous disease of the lower limbs: an observational study conducted by French angiologists. Phlebolymphology. 2006;13:6-16.
14. Allaert FA. Pain scales in venous disease: methodological reflections. Medicographia. 2006;28:137-140.
15. Veverkova L, Jedlika V, Wechsler J, et al. Analysis of the various procedures used in great saphenous vein surgery in the Czech Republic and benefit of Daflon 500 mg on postoperative symptoms. Phlebolymphology. 2006:13:195-201.
16. Jantet G; RELIEF Study Group. Chronic Venous Insufficiency: Worldwide Results of the RELIEF Study. Angiology. 2002;53:245-256.
17. Guillot B, Guilhou JJ, de Champvallins M, et al. A long term treatment with a venotropic drug: results on efficacy and safety of Daflon 500 mg in chronic venous insufficiency. Int Angiol. 1989;8:s67-s71.
18. Coleridge-Smith P, Lok C, Ramelet AA. Bénéfice thérapeutique de la FFPM dans le traitement des symptômes associés aux ulcères veineux de jambe: une méta-analyse. J Mal Vasc. 2007;32:s38
19. Ramelet A-A and the experts of the international consensus symposium of Siena 2005. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clinical Hemorheol Microcirc. 2005;33:309-319.
20. Nicolaides AN, Allegra C, Bergan J, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol. 2008;27:1-59.
21. Lyseng-Williamson A, Perry CM. Micronised purified flavonoid fraction. A review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs. 2003;63:71-100.
22. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg. 2005;30:198-208.